title: In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
abstract: Because modulation of P-glycoprotein (Pgp) through inhibition or induction can lead to drug-drug interactions by altering intestinal, central nervous system, renal, or biliary efflux, it is anticipated that information regarding the potential interaction of drug candidates with Pgp will be a future regulatory expectation. Therefore, to be able to utilize in vitro Pgp inhibition findings to guide clinical drug interaction studies, the utility of five probe substrates (calcein-AM, colchicine, digoxin, prazosin, and vinblastine) was evaluated by inhibiting their Pgp-mediated transport across multidrug resistance-1-transfected Madin-Darby canine kidney cell type II monolayers with 20 diverse drugs having various degrees of Pgp interaction (e.g., efflux ratio, ATPase, and calcein-AM inhibition). Overall, the rank order of inhibition was generally similar with IC(50) values typically within 3- to 5-fold of each other. However, several notable differences in the IC(50) values were observed. Digoxin and prazosin were the most sensitive probes (e.g., lowest IC(50) values), followed by colchicine, vinblastine, and calcein-AM. Inclusion of other considerations such as a large dynamic range, commercially available radiolabel, and a clinically meaningful probe makes digoxin an attractive probe substrate. Therefore, it is recommended that digoxin be considered as the standard in vitro probe to investigate the inhibition profiles of new drug candidates. Furthermore, this study shows that it may not be necessary to generate IC(50) values with multiple probe substrates for Pgp as is currently done for cytochrome P450 3A4. Finally, a strategy integrating results from in vitro assays (efflux, inhibition, and ATPase) is provided to further guide clinical interaction studies.
authors.affiliation: Preclinical Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Inc., Research Triangle Park, NC 27709, USA.
authors.forename: Jarkko
authors.initials: J
authors.lastname: Rautio
authors.forename: Joan E
authors.initials: JE
authors.lastname: Humphreys
authors.forename: Lindsey O
authors.initials: LO
authors.lastname: Webster
authors.forename: Anand
authors.initials: A
authors.lastname: Balakrishnan
authors.forename: John P
authors.initials: JP
authors.lastname: Keogh
authors.forename: Jeevan R
authors.initials: JR
authors.lastname: Kunta
authors.forename: Cosette J
authors.initials: CJ
authors.lastname: Serabjit-Singh
authors.forename: Joseph W
authors.initials: JW
authors.lastname: Polli
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000166:Acridines / Q000494:pharmacology; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000465:Algorithms; D000818:Animals; D002460:Cell Line; D004285:Dogs; D004347:Drug Interactions; D005452:Fluoresceins / Q000378:metabolism; D005456:Fluorescent Dyes / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D044005:Tetrahydroisoquinolines / Q000494:pharmacology
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000166:Acridines; D005452:Fluoresceins; D005456:Fluorescent Dyes; D004364:Pharmaceutical Preparations; D044005:Tetrahydroisoquinolines; C085925:calcein AM; D000251:Adenosine Triphosphatases; C083501:Elacridar